Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook Valneva - 20 Mar 2024 Valneva Reports Full Year 2023 Results and Provides Business Updates and Outlook ... More
Interim recommendations for use of the Valneva VLA2001 vaccine against COVID-19 World Health Organization (WHO) - 18 Aug 2022 Interim recommendations for use of the Valneva VLA2001 vaccine against COVID-19 ... More
Valneva seeks help in deciding what to do with COVID vaccine plant in Scotland: report Fierce Pharma - 15 Jun 2023 Valneva seeks help in deciding what to do with COVID vaccine plant in Scotland: report ... More
Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates Valneva - 09 Nov 2023 Valneva Reports Nine-Month 2023 Financial Results and Provides Corporate Updates ... More
Background document on the Valneva VLA2001 vaccine against COVID-19 World Health Organization (WHO) - 18 Aug 2022 Background document on the Valneva VLA2001 vaccine against COVID-19 ... More
Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya ... Valneva - 13 Nov 2023 Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya ... ... More
EMA Accepts Valneva's Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment Valneva - 27 Nov 2023 EMA Accepts Valneva's Chikungunya Vaccine Marketing Authorization Application for Accelerated Assessment ... More
Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine Valneva - 10 Jan 2024 Valneva Vaccinates First Participant in Pediatric Trial of Single-Shot Chikungunya Vaccine ... More
Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® Valneva - 04 Dec 2023 Valneva Reports Positive 24-Month Antibody Persistence Data for its Single-Shot Chikungunya Vaccine IXCHIQ® ... More
Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri® Valneva - 08 Sep 2022 Valneva and VBI Vaccines Announce European Partnership for Marketing and Distribution of PreHevbri® ... More
Valneva Announces Sale of Priority Review Voucher for $103 Million Valneva - 05 Feb 2024 Valneva Announces Sale of Priority Review Voucher for $103 Million ... More
Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 Valneva - 04 Dec 2023 Pfizer and Valneva Complete Recruitment for Phase 3 VALOR Trial for Lyme Disease Vaccine Candidate, VLA15 ... More
Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration Valneva - 16 Sep 2022 Valneva and IDT Biologika Agree on Termination of their COVID-19 Collaboration ... More
Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate Valneva - 23 Dec 2022 Valneva Completes BLA Submission to U.S. FDA for its Single-Shot Chikungunya Vaccine Candidate ... More
Unveiling the Lesser-Known Impact of Climate Change: The Rise of Mosquito-Borne Diseases Valneva - 09 Jan 2024 Unveiling the Lesser-Known Impact of Climate Change: The Rise of Mosquito-Borne Diseases ... More